JP2025090801A5 - - Google Patents

Info

Publication number
JP2025090801A5
JP2025090801A5 JP2025041934A JP2025041934A JP2025090801A5 JP 2025090801 A5 JP2025090801 A5 JP 2025090801A5 JP 2025041934 A JP2025041934 A JP 2025041934A JP 2025041934 A JP2025041934 A JP 2025041934A JP 2025090801 A5 JP2025090801 A5 JP 2025090801A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025041934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025090801A (ja
Filing date
Publication date
Priority claimed from JP2020213211A external-priority patent/JP7410846B2/ja
Application filed filed Critical
Publication of JP2025090801A publication Critical patent/JP2025090801A/ja
Publication of JP2025090801A5 publication Critical patent/JP2025090801A5/ja
Pending legal-status Critical Current

Links

JP2025041934A 2015-01-12 2025-03-14 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能 Pending JP2025090801A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562102245P 2015-01-12 2015-01-12
US62/102,245 2015-01-12
JP2020213211A JP7410846B2 (ja) 2015-01-12 2020-12-23 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2023015047A JP7719816B2 (ja) 2015-01-12 2023-02-03 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023015047A Division JP7719816B2 (ja) 2015-01-12 2023-02-03 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能

Publications (2)

Publication Number Publication Date
JP2025090801A JP2025090801A (ja) 2025-06-17
JP2025090801A5 true JP2025090801A5 (https=) 2025-11-06

Family

ID=56406560

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2017555445A Pending JP2018501322A (ja) 2015-01-12 2016-01-12 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2020213210A Active JP7410845B2 (ja) 2015-01-12 2020-12-23 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2020213211A Active JP7410846B2 (ja) 2015-01-12 2020-12-23 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2023015047A Active JP7719816B2 (ja) 2015-01-12 2023-02-03 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2023015026A Active JP7719815B2 (ja) 2015-01-12 2023-02-03 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2025041934A Pending JP2025090801A (ja) 2015-01-12 2025-03-14 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2025041931A Pending JP2025094038A (ja) 2015-01-12 2025-03-14 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能

Family Applications Before (5)

Application Number Title Priority Date Filing Date
JP2017555445A Pending JP2018501322A (ja) 2015-01-12 2016-01-12 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2020213210A Active JP7410845B2 (ja) 2015-01-12 2020-12-23 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2020213211A Active JP7410846B2 (ja) 2015-01-12 2020-12-23 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2023015047A Active JP7719816B2 (ja) 2015-01-12 2023-02-03 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能
JP2023015026A Active JP7719815B2 (ja) 2015-01-12 2023-02-03 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025041931A Pending JP2025094038A (ja) 2015-01-12 2025-03-14 トール様受容体4アンタゴニストの炎症促進性およびアジュバント機能

Country Status (7)

Country Link
US (7) US20180318414A1 (https=)
EP (2) EP4681782A3 (https=)
JP (7) JP2018501322A (https=)
AU (2) AU2021200638B2 (https=)
CA (1) CA2973585A1 (https=)
ES (1) ES3057334T3 (https=)
WO (1) WO2016115097A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180318414A1 (en) 2015-01-12 2018-11-08 Children's Medical Center Corporation Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists
AU2017356295A1 (en) * 2016-11-14 2019-05-23 Beth Israel Deaconess Medical Center Compositions and methods of treating cancer
CA3135291A1 (en) * 2019-03-29 2020-10-08 The Brigham And Women's Hospital, Inc. Targeted synergistic cancer immunotherapy
AU2020363707A1 (en) * 2019-10-07 2022-04-28 Northwest Biotherapeutics, Inc. In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
JP7753205B2 (ja) * 2019-11-18 2025-10-14 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン 超活性樹状細胞は養子細胞移植に基づく持続性抗腫瘍免疫を可能にする
EP4061409A4 (en) * 2019-11-18 2023-12-27 Children's Medical Center Corporation Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy
CN114894910B (zh) * 2022-03-18 2023-10-20 重庆医科大学附属第一医院 1-棕榈酰-2-花生四烯酰-sn-甘油-3-磷酸胆碱检测试剂的新用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
WO2004006910A1 (de) * 2002-07-15 2004-01-22 Norbert Leitinger Lipidoxidationsprodukte zur hemmung von entzündungen
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
JP2010505883A (ja) * 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
WO2011013682A1 (ja) 2009-07-27 2011-02-03 株式会社神戸製鋼所 配線構造およびその製造方法、並びに配線構造を備えた表示装置
US20130108661A1 (en) 2010-02-05 2013-05-02 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
BR112012027745A2 (pt) 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
CN104066706B (zh) * 2011-12-12 2017-12-19 脉管生物生长有限公司 炎症的治疗
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
WO2015091787A1 (en) 2013-12-18 2015-06-25 Julius-Maximilians-Universität Würzburg Galactose oxidase treatment of dendritic cells to improve their immunogenicity
US20180318414A1 (en) * 2015-01-12 2018-11-08 Children's Medical Center Corporation Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists
CA2982614A1 (en) 2015-05-07 2016-11-10 Baylor College Of Medicine Dendritic cell immunotherapy
US10813988B2 (en) 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
CA3028654A1 (en) 2016-06-27 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Therapeutic antitumor combination of a tlr4 ligand with other treatments
WO2018067302A2 (en) 2016-09-19 2018-04-12 North Western University Therapeutic effects of cellular delivery of small molecules and macromolecules with liposomal spherical nucleic acids
CA3098868A1 (en) 2018-05-03 2019-11-07 L.E.A.F. Holdings Group Llc Carotenoid compositions and uses thereof
AU2020363707A1 (en) 2019-10-07 2022-04-28 Northwest Biotherapeutics, Inc. In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
JP7753205B2 (ja) 2019-11-18 2025-10-14 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン 超活性樹状細胞は養子細胞移植に基づく持続性抗腫瘍免疫を可能にする
EP4061409A4 (en) 2019-11-18 2023-12-27 Children's Medical Center Corporation Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy

Similar Documents

Publication Publication Date Title
JP2024116190A5 (https=)
JP2023171775A5 (https=)
JP2022184985A5 (https=)
JP2023103258A5 (https=)
JP2025176106A5 (https=)
JP2024114921A5 (https=)
JP2024161376A5 (https=)
JP2023145572A5 (https=)
JP2025160243A5 (https=)
JP2023181322A5 (https=)
JP2025098156A5 (https=)
JP2024045126A5 (https=)
JP2025094038A5 (https=)
JP2025090801A5 (https=)
JP2024149687A5 (https=)
JP2023093656A5 (https=)
JP2024099585A5 (https=)
JP2024099716A5 (https=)
JPWO2023196444A5 (https=)
JP2023085264A5 (https=)
JP2023156274A5 (https=)
JP2025084821A5 (https=)
JP2023100857A5 (https=)
JP2023078173A5 (https=)
JP2024059782A5 (https=)